DIAアカウントをお持ちの場合、サインインしてください。

サインイン

ユーザーIDをお忘れですか? or パスワードをお忘れですか?

- DIA AI Consortium – Detail Page
DIA AI Consortium — Phase 2Current

Phase 2: Active Initiatives

Phase 2 of the DIA AI Consortium is underway through December 2027, bringing together industry, health authorities, academia, technology organizations, and other stakeholders to advance responsible, practical uses of artificial intelligence in drug development. Building on Phase 1 foundational work, members are collaborating on implementation-oriented tools and guidance while exploring emerging AI applications in clinical trials.

At a Glance
Launch Year
2026
Organizations
40
Active Working Groups
Workstream 1: Implementation & Operationalization

Workstream 2: Innovation Incubator
Current Goals

What Phase 2 Is Working Toward

Phase 2 moves from foundational frameworks toward practical application and evaluation. The consortium is focused on: (1) translating Phase 1 work into reusable implementation resources; (2) exploring approaches to AI use-case classification, risk assessment, validation, monitoring, governance, and human oversight; (3) testing and refining approaches through member examples and real-world implementation experiences; and (4) examining emerging AI applications in clinical-trial design, execution, evidence generation, and related regulatory and operational considerations. Across both workstreams, members aim to share cross-sector learning and develop resources that remain useful as AI capabilities evolve.

Governance & Leadership

Executive Committee

The consortium is a DIA-convened, pre-competitive collaboration guided by an Executive Committee and informed by participating organizations across the life sciences ecosystem. The Executive Committee supports strategic direction, prioritization, and alignment across workstreams, while DIA coordinates program activities and external engagement. Industry, academic, patient, technology, and health-authority perspectives inform the initiative’s work.

✕
Christina Mack
Christina Mack, Ph.D.
IQVIA
Executive Committee, DIA AI Consortium

Christina Mack, Ph.D. is Senior Vice President of Applied AI Science within the AI and Technology Solutions (ATS) business, where she is responsible for driving scientific and technical innovation across the organization that has direct impact on patient health. Dr. Mack also leads the IQVIA Surveillance and Agile Analytics Team, which partners with biopharma and elite sports organizations such as NFL and NBA to prevent disease, reduce injuries and improve population health and safety.

In addition to this role, she serves as Chief Scientific Officer of IQVIA's Real World Evidence business, focused on applying advanced analytics and data science — including artificial intelligence — to improve population health, strengthen clinical evidence, and support regulatory decision-making.

✕
Leon Rozenblit
Leon Rozenblit
Beth Israel / Yale SOM
Executive Committee, DIA AI Consortium

Leon Rozenblit is a nationally recognized thought leader at the intersection of clinical research informatics and AI governance. As Co-Founder and Executive Committee member of the DCI Network at Beth Israel Deaconess Medical Center, Harvard Medical School, he has co-organized two AI governance conferences and published peer-reviewed research on multi-stakeholder approaches to responsible AI in healthcare.

A pioneer of "registry science," he has led dozens of national-scale registry programs and brings an interdisciplinary perspective spanning informatics, cognitive science, statistics, and law to bridge IT, scientific, and senior executive teams. He also advises health technology startups as Entrepreneur in Residence at Yale Ventures.

✕
Sridevi Nagarajan
Sridevi Nagarajan
Ayusarogya Ltd.
Executive Committee, DIA AI Consortium

An influential and data-driven executive professional with a robust background in the Pharmaceutical and Public Health sectors, bringing a unique blend of expertise in leading digital transformation initiatives and leveraging data to guide corporations through complex business changes.

Recognized as a thought leader and industry expert in the data, digital health, and AI ecosystem, Sridevi excels at understanding industry trends and developing strategic perspectives to guide digital health and AI partnerships and investments. She brings high-level analytical skills and deep expertise in drug development, clinical, safety and regulatory processes, data management, digital innovation, and governance.

✕
Stephanie Rosner
Stephanie Rosner
DIA
Senior Scientific Program Manager, AI

Stephanie Rosner serves as Senior Scientific Program Manager for Artificial Intelligence at DIA, where she leads the development and coordination of the DIA AI Consortium. She works closely with co-chairs, working group leads, and member organizations to advance trustworthy AI frameworks across the life sciences industry.

✕
Carrie Nielson
Carrie Nielson
Gilead
Executive Committee, DIA AI Consortium

Carrie Nielson is a Director of Epidemiology at Gilead Sciences, where she focuses on regulatory policy for RWE and on rigorous observational research methods that support reliable evidence generation.

She collaborates with industry, academic, and regulatory colleagues, including through the DIA Artificial Intelligence Consortium, helping align on AI use-case development, risk-proportionate validation approaches, and defensible oversight and documentation models. Her work centers on translating emerging regulatory expectations into practical, inspection-ready systems and procedures that enable sound adoption of RWE and AI in drug development contexts.

✕
Venkatraman Balasubramanian
Venkatraman Balasubramanian
VB Insights LLC
Executive Committee, DIA AI Consortium

Bala heads VB Insights, an advisory firm for the Healthcare and Life Sciences sector. Bala brings over 36 years of experience. During his long tenure, he has been responsible for the introduction of Web, document management, global team collaboration, and regulatory information management applications to large pharma.

Until recently, Bala was Head of the Healthcare and Life Sciences at Orion Innovation. As an entrepreneur and a thought leader, he has been involved in initiatives to transform regulatory affairs from a document-centric function to a data-driven function. Bala has been associated with DIA for more than 17 years, leading DIA RIM Reference Model workstream and DIA AI Consortium Regulatory Frameworks and Terminology workstream.

How We're Working

Active Workstreams

Workstream 1: Implementation and Operationalization

Building on Phase 1 foundations, Workstream 1 is exploring practical ways to apply AI frameworks within organizations. Areas under development include use-case intake and classification, risk scoring, organizational readiness, validation and testing, lifecycle monitoring, AI governance, and meaningful human oversight. Members are working on reusable playbooks, checklists, examples, and potential pilots to help test and refine approaches across different implementation settings.

Workstream 2: Innovation Incubator

Workstream 2 is examining emerging AI opportunities and adoption challenges in drug development, with an initial emphasis on accelerating clinical trials. Discussion areas include AI-enabled trial planning and execution, evidence generation, the evolving technology and regulatory landscape, and considerations such as human oversight, traceability, and the gap between technical capability and real-world deployment. Members are shaping a coordinated approach for assessing and communicating the state of the field.

Cross-Workstream Collaboration

The workstreams share insights on validation, governance, risk, evidence, and oversight to connect practical implementation needs with emerging applications.

Stay Involved

Consortium Collaboration Model

Consortium members collaborate through regular workstream meetings and quarterly all-consortium sessions. The Executive Committee meets consistently to provide strategic input and maintain cross-workstream alignment. Additional subgroup sessions and member updates support the development and review of emerging work. Meeting details and participation information are shared directly with consortium members.
Impact & Outputs

Deliverables in Progress

Phase 2 work is progressing toward practical resources and shared analysis. Current areas of development include:

Implementation-oriented playbooks and supporting resources addressing AI classification, risk assessment, validation, governance, and oversight.

Exploration of member use cases and pilots to test and improve the usability of existing frameworks.

Analysis of emerging AI applications in clinical trials, including the distinction between technologies that are technically possible and those demonstrably adopted in practice.

Potential publications and other knowledge-sharing activities to communicate findings to the broader life sciences community.

Partners & Collaborators

Participating Organizations

Phase 2 brings together participating organizations spanning biopharmaceutical companies, health authorities, academic and research institutions, technology and consulting organizations, and patient perspectives. These diverse contributors support pre-competitive dialogue and practical cross-sector learning.

Artos AI
AstraZeneca
Ayusarogya Ltd.
Beczek Consulting
Beth Israel Deaconess Medical Center–Harvard Medical School; Yale Ventures
Black Swan Causal Labs
CDSCO
Clintegrity
C-Path
EMA
FDA
GeneAld
Georgetown University Lombardi Comprehensive Cancer Center
Gilead
Harvard Business School
Health Canada
Healthcare Innovation Catalysts
HSA
IDC
IQVIA
LeapAhead Solutions
MHRA
National Academies of Sciences, Engineering, and Medicine
NexTrial.ai
Panoptive Health
Parexel
PiCC United (Patient Involvement and Collaboration Community United)
PMDA
Scimitar
Stanford University
Stuyvenberg Advisory Group
Turkish Medicines and Medical Devices Agency
ThirdEye Consulting
UCB
University of Modena and Reggio Emilia
University of Ottawa
University of Phoenix
VB Insights
Xogene
Zipp AI
Latest From Phase 2

Recent Updates

OCTOBER–NOVEMBER 2026 | Translating Phase 1 into practice

Workstream 1 members are developing the direction for practical implementation resources, with discussion centered on classification and risk, validation, organizational readiness, governance, and human oversight.

OCTOBER 2026 | Exploring AI-enabled clinical-trial acceleration

Workstream 2 discussions have focused on emerging AI applications across the clinical-trial lifecycle and the challenge of evaluating promising technologies alongside evidence of real-world adoption.

AUGUST 2026 | Phase 2 collaboration underway

The consortium convened its Phase 2 kickoff, bringing members together around implementation-oriented priorities and an Innovation Incubator focused initially on clinical trials.

Get Involved

Join the Consortium

Phase 2 is open to partner organizations dedicated to advancing trustworthy AI in the life sciences.

最新情報や機会を逃さないで

DIAのメールを購読すれば、常に最新の業界情報やイベント情報を得ることができます。